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Acute aortic syndromes (AASs) are difficult to diagnose emergencies. Plasma soluble ST2 (sST2), 
a prognostic biomarker for heart failure, has been proposed as a diagnostic biomarker of AASs 
outperforming D-dimer, the current diagnostic standard. We performed a prospective diagnostic 
accuracy study of sST2 for AASs in the Emergency Department (ED). In 2017–2018, patients were 
enrolled if they had ≥1 red-flag symptoms (chest/abdominal/back pain, syncope, perfusion deficit) 
and a clinical suspicion of AAS. sST2 was detected with the Presage® assay. Adjudication was based 
on computed tomography angiography (CTA) or on diagnostic outcome inclusive of 30-day follow-up. 
297 patients were enrolled, including 88 with AASs. The median age was 67 years. In 162 patients with 
CTA, the median sST2 level was 41.7 ng/mL (IQR 29.4–103.2) in AASs and 34.6 ng/mL (IQR 21.4–51.5) 
in alternative diagnoses (P = 0.005). In ROC analysis, the AUC of sST2 was 0.63, as compared to 0.82 of 
D-dimer (P < 0.001). Sensitivity and specificity values of sST2 associated with different cutoffs were: 
95.5% and 10.8% (≥12 ng/mL), 84.1% and 29.7% (≥23.7 ng/mL), 35.2% and 85.1% (≥66.5 ng/mL). 
Results were similar in the full cohort. In conclusion, in patients from a European ED, plasma sST2 
provided modest accuracy for diagnosis of AASs.
Acute aortic syndromes (AASs), which include acute aortic dissection (AAD), intramural aortic hematoma 
(IMH), penetrating aortic ulcer (PAU) and spontaneous aortic rupture (SAR), are severe cardiovascular emer-
gencies affecting 5–10 per 100.000 individuals a year1. A conclusive diagnosis of AASs requires advanced aortic 
imaging, typically computed tomography angiography (CTA), which uses ionizing radiations and may cause 
contrast-induced nephropathy and anaphylaxis. However, selection of the right patient to image with CTA is 
cumbersome, because AASs present with unspecific symptoms such as truncal pain, syncope, neurological defi-
cits and hindlimb ischemia. These are leading causes of Emergency Department (ED) visits worldwide, and most 
patients with these symptoms are affected by more common conditions, such as acute coronary syndromes, gas-
trointestinal diseases and muscle-skeletal pain. Hence, the misdiagnosis rate of AASs is high, affecting clinical 
outcomes2–4. Increasing use of CTA in EDs has led to a high number of CTA exams requested for suspected AAS 
turning out negative, but has not substantially changed misdiagnosis rates, indicating that pre-test patient selec-
tion remains a key node5–7. Development of reliable diagnostic biomarkers discriminating AASs could positively 
impact on their diagnostic workup, as for other cardiovascular emergencies such as acute coronary syndromes 
and pulmonary embolism8,9.
So far, potential biomarkers of AASs have been searched for within aortic layers (e.g. smooth muscle myosin, 
soluble elastin fragments, calponin, CD40 ligand), within inflammation/remodeling pathways (e.g. matrix met-
alloproteinases) and within coagulation processes mobilized by blood exposure to non-endothelial surfaces (e.g. 
platelets, D-dimer)10. Currently, D-dimer is the only biomarker clinically applicable to the workup of AASs11,12. 
Owing to high sensitivity, D-dimer can be used for diagnostic rule-out of AASs, if the pre-test probability is suf-
ficiently low13. However, D-dimer can be increased by several conditions such as inflammation, infection, cancer, 
trauma and age, leading to low diagnostic specificity. On these grounds, the quest for additional diagnostic bio-
markers for AASs remains open and vibrant.
ST2 (suppression of tumorigenicity 2, encoded by interleukin 1 receptor-like 1 or IL1RL-1) is a member 
of the interleukin-1 receptor family, regulating immune-responses14. Soluble ST2 (sST2), a truncated form 
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of transmembrane ST2, is secreted into the circulation and functions as a decoy receptor for interleukin-33. 
Evidence has accumulated that sST2 is up-regulated in cardiac cells upon myocardial strain and several studies 
have established plasma sST2 as a biomarker for clinical risk prediction in patients affected by heart failure15–19. 
The role of sST2 within vascular tissues and in the context of aortic disease is largely unknown20. However, Wang 
et al. recently reported that plasma sST2, measured with a research-grade assay, showed striking diagnostic accu-
racy for AASs and outperformed D-dimer, in a Chinese patient cohort21. Since plasma sST2 levels can be meas-
ured with a clinical-grade assay already approved for patient use, we sought to further evaluate it as a diagnostic 
biomarker for AASs in an independent prospective cohort of acute patients from a European ED.
Results
Study population. In the study period, 297 patients with any pre-defined red-flag symptom (chest/abdom-
inal/back pain, syncope, perfusion deficit) and a clinical suspicion of an AAS, were enrolled. Presenting symp-
toms were the following: anterior chest pain (189, 63.6%), posterior chest pain (114, 38.4%), abdominal pain (66, 
22.2%), back pain (25, 8.4%), syncope (34, 11.4%), perfusion deficit (20, 6.7%). The demographic and clinical 
characteristics of study patients are reported in Table 1. The prevalence of risk factors for AASs and the corre-
sponding aortic dissection detection risk score are presented in Table 2. 243 patients (81.8%) were classified at low 
pre-test clinical probability of AAS, according to ESC guidelines13.
Diagnostic work-up and case adjudication. The diagnostic workup conducted during the index ED 
visit included chest X-ray in 166 (55.9%) patients, focused transthoracic echocardiography in 136 (45.8%), CTA 
in 162 (54.5%), transesophageal echocardiography (TEE) in 1 (0.3%) and coronary angiography in 3 (1%). 30-day 
follow-up data was obtained for 287 (96.6%) patients. 147 (49.5%) patients were admitted to hospital. Amongst 
10 patients lacking follow-up data, 7 were subjected to advanced aortic imaging in the ED excluding an AAS. 
Diagnostic data allowing final case adjudication are detailed in Fig. 1.
An AAS was adjudicated in 88 (29.6%) patients, all subjected to CTA. The AAS types were: 46 (15.5%) 
Stanford type A AADs, 20 (6.7%) Stanford type B AADs, 18 (6.1%) IMHs, 3 (1%) SARs and 1 (0.3%) PAU. In 
209 (70.4%) patients, an AAS was excluded and the following alternative diagnoses (AltDs) were adjudicated: 
skeletal-muscle pain (45, 15.2%), gastrointestinal disease (28, 9.4%), acute coronary syndrome (18, 6.1%), non 
AAS-related syncope (16, 5.4%), other aortic disease (15, 5.1%), pericarditis (12, 4%), pleurisy/pneumonia (9, 
3%), stroke (1, 0.3%), pulmonary embolism (1, 0.3%) and other conditions (64, 21.5%). The demographic and 
clinical characteristics of study patients classified by diagnostic outcome are reported in Table 1. Patients affected 
by AASs had significantly higher levels of white blood cells (WBCs), creatinine, troponin and D-dimer.
CTA-based adjudication. We first analyzed the diagnostic characteristics of plasma sST2 within patients 
subjected to CTA (n = 162, 88 with AASs), which represents the imaging gold standard to rule-in/out AASs. 
The demographic and clinical characteristics of patients with AltDs subjected to CTA (n = 74) are reported in 
Supplementary Table 1. The median plasma sST2 level was 41.7 ng/mL (IQR 29.4–103.2) in patients with AASs 
Variable
Total patients 
(n = 297) AASs (n = 88) AltDs (n = 209) P-value
Female gender 94 (31.6%) 26 (29.5%) 68 (32.5%) 0.61
Age [y] 67 (55–78) 72 (59.5–80) 65 (53–77) 0.04
Hypertension 176 (59.3%) 62 (70.5%) 114 (54.5%) 0.011
Diabetes 27 (9.1%) 7 (8%) 20 (9.6%) 0.66
Dyslipidemia 18 (6.1%) 3 (3.4%) 15 (7.2%) 0.21
Smoking 87 (29.3%) 26 (29.5%) 61 (29.2%) 0.95
Drug use 3 (1%) 2 (2.3%) 1 (0.5%) 0.16
Coronary art. dis. 37 (12.5%) 6 (6.8%) 31 (14.8%) 0.06
Active cancer 2 (0.7%) 0 (0%) 2 (1%) 0.36
Periph. art. dis. 1 (0.3%) 0 (0%) 1 (0.5%) 0.52
Abdominal aortic an. 14 (4.7%) 5 (5.7%) 9 (4.3%) 0.61
Previous AAS 10 (3.4%) 4 (4.5%) 6 (2.9%) 0.47
Systolic BP [mmHg] 140 (120–160) 140 (110–170) 140 (125–160) 0.48
Diastolic BP [mmHg] 80 (70–90) 80 (60–95) 80 (75–90) 0.04
Heart rate [bpm] 75 (68–87) 72 (64–83) 75 (70–89) 0.15
Time from onset [h] 4 (2–11) 3 (2–6) 5 (2–14) 0.02
WBC count [*103/μL]A 9.07 (7.22–11.71) 11.66 (9.1–14.35) 8.14 (6.78–10.45) <0.001
Creatinine [mg/dL]B 0.97 (0.82–1.16) 1.06 (0.86–1.21) 0.93 (0.81–1.12) 0.004
Troponin T [ng/mL]C 11 (7–23) 20 (10–41) 10 (5–18) <0.001
D-dimer [ng/mL]D 780 (331.5–3466.5) 6301 (1813–28646) 471 (265.5–1002.5) <0.001
Table 1. Demographic and clinical characteristics of prospectively enrolled patients. An = 294; Bn = 293; 
Cn = 262; Dn = 211. Categorical variables are presented as n (%) and continuous variables as median (25th-
75th percentile). AASs = acute aortic syndrome; AltDs: alternative diagnoses; an. = aneurysm; art. = artery; 
BP = blood pressure; dis. = disease; sy. = syndrome; thor. = thoracic.
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and 34.6 ng/mL (IQR 21.4–51.5) in patients with AltDs (P = 0.005, Fig. 2a). Median sST2 levels were 40.8 ng/mL 
(IQR 24–146.8) in type A AADs, 45.7 ng/mL (IQR 40–79.2) in type B AADs, 35.2 ng/mL in IMHs (IQR 30.1–71.5), 
54.2 ng/mL (IQR 44.7–55.3) in SARs and 61.9 ng/mL in PAUs (P = 0.67; Fig. 2b). The levels of sST2 in different 
types of AltDs did not significantly differ (P = 0.34, Supplementary Fig. 1a).
sST2 levels showed linear correlation with WBC count (r = 0.3, P < 0.001), creatinine (r = 0.19, P = 0.018) 
and D-dimer (r = 0.21, P = 0.018), but not with troponin T (r = 0.14, P = 0.1), and non-linear correlation with 
all variables (WBC count, ρs = 0.26, P < 0001.; creatinine, ρs = 0.19, P = 0.014; D-dimer, ρs = 0.36, P < 0.001; tro-
ponin, ρs = 0.25, P = 0.04). In patients with AASs, sST2 levels showed linear correlation with WBC count (Fig. 3), 
and non-linear correlation with WBC count (ρs = 0.26, P = 0.014), creatinine (ρs = 0.27, P = 0.014) and D-dimer 
(ρs = 0.28, P = 0.017), but not with troponin T (ρs = 0.17, P = 0.17). In patients with AltDs, sST2 levels showed 
linear correlation with WBC count (r = 0.30; P = 0.009) and D-dimer (r = 0.26; P = 0.04), but not with creatinine 
(r = 0.06; P = 0.64) and troponin (r = 0.2; P = 0.1); non-linear correlation was found with troponin (ρs = 0.29, 
P = 0.017), but not with WBC count (ρs = 0.09, P = 0.46), creatinine (ρs = 0.08, P = 0.52) and D-dimer (ρs = 0.24, 
P = 0.06).
The receiver operating characteristic (ROC) curves of sST2 and D-dimer for diagnosis of AASs are shown 
in Fig. 4a,b. The area under the curve (AUC) values of sST2 and D-dimer significantly differed (P < 0.001). In 
patients sampled within 24 hours from symptom onset, the AUC of sST2 (n = 118) was 0.591 (95%CI 0.497–
0.681), while the AUC of D-dimer (n = 97) was 0.842 (95%CI 0.753–0.908; P < 0.001 vs sST2). In patients at low 
clinical probability of AAS (as defined by ADD-RS ≤ 1), the AUC of sST2 (n = 120) was 0.661 (95%CI 0.569–
0.745), while the AUC of D-dimer (n = 98) was 0.768 (95%CI 0.672–0.848; P = 0.12 vs sST2).
Using a conventional cutoff of 500 ng/mL, D-dimer had a sensitivity of 95.8% (95%CI 88.1–99.1%), a specific-
ity of 30.7% (95%CI 19.6–43.7%), a LR+ of 1.38 (95%CI 1.2–1.6) and a LR− of 0.14 (95%CI 0.04–0.4) for AASs. 
For sST2, the cutoff maximizing the sensitivity and specificity was 66.5 ng/mL. Table 3 reports the diagnostic test 
characteristics of sST2 for AASs at different selected cutoffs.
Diagnostic outcome-based adjudication. We next evaluated the diagnostic test characteristics of 
plasma sST2 in the whole study cohort per prospective enrolment and diagnostic outcome adjudication (n = 297, 
Tables 1 and 2). The median plasma sST2 level was 41.7 ng/mL (IQR 29.4–103.2) in AASs and 30.1 ng/mL (IQR 
20–43.8) in AltDs (P < 0.001; Fig. 2c). The levels of sST2 in different types of AltDs did not significantly differ 
(P = 0.44; Supplementary Fig. 1b).
In patients with AltDs, sST2 showed linear correlation with WBC count (r = 0.24, P < 0.001), creatinine 
(r = 0.22, P = 0.001), D-dimer (r = 0.42, P < 0.001) and troponin (r = 0.17, P = 0.02); non-linear correlation was 
found with creatinine (r = 0.16, P = 0.025), D-dimer (r = 0.25, P = 0.03) and troponin (r = 0.19, P = 0.09), but not 
with WBC count (r = 0.05, P = 0.43). In patients with an AltD of acute coronary syndrome, plasma sST2 levels 
showed non-linear correlation with troponin T (ρs = 0.63, P = 0.01), but not with WBC count (ρs = 0.17, P = 0.51), 
creatinine (ρs = 0.32, P = 0.22) and D-dimer (ρs = 0.04, P = 0.89).
The ROC curves of sST2 and D-dimer for diagnosis of AASs in the full study cohort are shown in Fig. 4c,d. 
The AUC values of sST2 and D-dimer significantly differed (P < 0.001). In patients sampled within 24 hours from 
symptom onset, the AUC of sST2 (n = 223) was 0.675 (95%CI 0.61–0.736), while the AUC of D-dimer (n = 160) 
was 0.917 (95%CI 0.863–0.955; P < 0.001 vs sST2). In patients at low clinical probability of AAS, the AUC of sST2 
Variable Total patients (n = 297) AASs (n = 88) AltDs (n = 209) P-value
History
Marfan/conn. tissue dis. 1 (0.3%) 0 (0%) 1 (0.5%) 0.52
Family history of AAS 7 (2.4%) 2 (2.3%) 5 (2.4%) 0.95
Aortic valve disease 21 (7.1%) 7 (8%) 14 (6.7%) 0.7
Recent aortic manipulation 3 (1%) 1 (1.1%) 2 (1%) 0.89
Thoracic aortic aneurysm 40 (13.5%) 21 (23.9%) 19 (9.1%) 0.001
Pain
Sudden pain 146 (49.2%) 55 (62.5%) 91 (43.5%) 0.001
Severe pain 73 (24.6%) 28 (31.8%) 45 (21.5%) 0.003
Ripping/tearing pain 32 (10.8%) 20 (22.7%) 12 (5.7%) 0.06
Physical findings
Pulse deficit 23 (7.7%) 16 (18.2%) 7 (3.3%) <0.001
Neurologic deficit 13 (4.4%) 7 (8%) 6 (2.9%) 0.05
New diastolic murmur 1 (0.3%) 1 (1.1%) 0 (0%) 0.12
Hypotension 18 (6.1%) 15 (17%) 3 (1.4%) <0.001
ADD risk score
ADD risk score = 0 88 (29.7%) 11 (12.5%) 77 (36.8%) <0.001
ADD risk score = 1 155 (52.2%) 45 (51.1%) 110 (52.6%) 0.81
ADD risk score = 2–3 54 (18.2%) 32 (36.4%) 22 (10.5%) <0.001
Table 2. Aortic dissection detection risk factors and associated risk score of study patients. AASs: acute aortic 
syndromes; ADD: aortic dissection detection; AltDs: alternative diagnoses; conn.: connective; dis.: disease.
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(n = 243) was 0.717 (95%CI 0.655–0.772), while the AUC of D-dimer (n = 168) was 0.867 (95%CI 0.806–0.914; 
P = 0.002 vs sST2).
Using a cutoff of 500 ng/mL, D-dimer had a sensitivity of 95.8% (95%CI 88.1–99.1%), a specificity of 53.6% 
(95%CI 45–62%), a LR + of 2.06 (95%CI 1.7–2.5) and a LR− of 0.079 (95%CI 0.03–0.2) for AASs. The diag-
nostic test characteristics of sST2 for AASs in the full study cohort are reported in Table 3. The cutoff maxi-
mizing the sensitivity and specificity of sST2 for AASs in the full cohort was 39.8 ng/mL. The diagnostic test 
Figure 1. Data used for diagnostic outcome adjudication. Cath: coronary angiography (cardiac catheterization 
laboratory); CR: chest X-ray; CTA: contrast-enhanced computed tomography angiography of the chest and 
abdomen; FoCUS: focused cardiac ultrasound; FU: follow-up; hosp. adm.: hospital admission; n.a.: not 
available; TEE: transesophageal echocardiography.
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characteristics associated with sST2 ≥ 39.8 ng/mL were: sensitivity 58% (95%CI 47–68.4%), specificity 70.8% 
(95%CI 64.1–76.9%), positive likelihood ratio (LR+) 1.99 (95%CI 1.5–2.6), negative likelihood ratio (LR−) 0.59 
(95%CI 0.5–0.8).
Discussion
In this single-center prospective study performed in a European ED, median plasma levels of sST2 measured 
with a clinical-grade assay were higher in patients with AASs than in patients with AltD. However, there was high 
inter-patient variability and the overall performance of sST2 for diagnosis AASs was modest. Furthermore, sST2 
proved inferior to D-dimer, a well-established biomarker of AASs already applied in clinical practice.
The present study post-dated the study by Wang et al. reporting high sensitivity and specificity of plasma sST2 
for AASs and indicating potential superiority of sST2 to D-dimer21. Several issues may cause the discrepancy 
between current and previous data. First, the present study involved a larger case-mix and an elder population, 
both typical of western country hospitals. Indeed, a recent study has reported significant variation in sST2 levels 
related to age, with 50 years as a critical cutoff22. Major differences in age between the present and the previous 
study may account for the discrepancy. Second, male gender has also been associated with higher sST2 levels. 
However, since gender distribution was similar between the two studies, this should not be regarded as a major 
confounder. Third, ethnic differences in sST2 levels between Asian and European populations may exist. Indeed, 
the lowest diagnostic accuracy estimates for D-dimer have been obtained in Asian studies23. Finally, the present 
study used a different assay for detection of sST2, i.e. the only one approved for patient use24. In Wang et al., the 
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Figure 2. Dot-plot and box-whisker representation of plasma sST2 levels in study patients, classified by: (a) 
dichotomic final diagnosis (adjudication based on CTA), (b) subtype of acute aortic syndrome, (c) dichotomic 
final diagnosis (adjudication based on diagnostic outcome). A-AAD: type A acute aortic dissection; AAS: acute 
aortic syndrome; ACS: acute coronary syndrome; alt. diag.: alternative diagnosis; B-AAD: type B AAD; IMH: 
intramural aortic hematoma; PAU: penetrating aortic ulcer; SAR: spontaneous aortic rupture.
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results of the research-grade R&D assay and the clinical-grade Presage assay strongly correlated. In the present 
study, we also found a significant albeit looser correlation between assays. Technical differences between sST2 
assays have already been documented25. However, additional ethinc specific differences between assays are also 
conceivable.
Together with previous evidence, current findings indicate that AASs may cause release of sST2 into the 
bloodstream, but the source and kinetics of this process remain largely unknown. In the present study, the levels 
of sST2 did not correlate with those of troponin T in AASs, indicating a loose relationship, if any, between plasma 
sST2 levels and myocardial damage. Instead, the levels of plasma sST2 and troponin T were correlated in patients 
with AltDs (including subgroup with acute coronary syndromes). In AASs, the levels of plasma sST2 correlated 
with WBC count and D-dimer, rather suggesting a pathophysiological link with inflammatory pathways engaged 
by acute aortic lesions8,26,27. Also in the study by Wang et al., plasma sST2 positively correlated with D-dimer 
concentrations and not with those of brain natriuretic peptide.
The present study has limitations. First, clinical suspicion of AASs, representing a key patient selection crite-
rion, falls short of a universal definition. Since the study was performed in a tertiary ED specialized in cardiovas-
cular emergencies, variation of physician’s gestalt and local practice might limit result generalizability. Second, 
due to ethical and clinical considerations (exposure to radiation and contrast medium), CTA could not be per-
formed as uniform gold standard. Treating physicians decided on CTA based on patient-level clinical reasoning 
irrespective of study participation, in compliance with an observational and non-interventional study protocol. 
A follow-up approach was used for pragmatic case adjudication based on 30-day outcomes. This method is rou-
tinely applied in diagnostic studies of cardiovascular emergencies in the ED such as pulmonary embolism and 
acute coronary syndromes and has been used in a previous multicenter study of AASs12,28–32. As compared to 
our previous work, the timeline of the follow-up was extended from 14 to 30 days, in order to fully cover both 
the acute and subacute phases of AASs. Very few patients with clinically mild forms of AASs (e.g. short uncom-
plicated IMHs or PAUs) might have been misdiagnosed. However, they could not substantially affect the study 
results. Accordingly, the results obtained in the CTA subgroup and in the full cohort did not differ.
In conclusion, in a European cohort of ED patients, plasma sST2 showed poor diagnostic accuracy for AASs. 
D-dimer, instead, confirmed its established diagnostic performance characterized by high sensitivity and mod-
erate specificity. Results substantially differ from those previously obtained in a larger and much younger cohort 
of Chinese patients. Further studies are needed to evaluate sST2 as a potential biomarker of aortic diseases in 
younger patients of non-Asian ethnicity.
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Figure 3. Scatter plots evaluating the correlation and linear regression between plasma sST2 and (a) white 
blood cell count, (b) creatinine, (c) troponin T and (d) D-dimer, in patients with acute aortic syndromes. Linear 
regression analysis data are presented as inset.
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Materials and Methods
Study design. We conducted a single-center prospective diagnostic accuracy study, in a large urban ED. The 
methods were carried out in accordance with the relevant guidelines and regulations. The local Human Ethics 
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Figure 4. Receiver operating characteristic (ROC) curves of plasma sST2 and D-dimer for diagnosis of acute 
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diagnostic outcome. AUC values are reported with their 95%CI in brackets.
Variable Case adjudication sST2 ≥ 12 ng/mLA sST2 ≥ 23.7 ng/mLB sST2 ≥ 66.5 ng/mLC
Sensitivity (%) CTA (n = 162) and diagnostic outcome (n = 297) 95.5% (95%CI 88.8–98.7%) 84.1% (95%CI 74.8–91%) 35.2% (95%CI 25.3–46.1%)
Specificity (%)
CTA (n = 162) 10.8% (95%CI 4.8–20.2%) 29.7% (95%CI 19.7–41.5%) 85.1% (95%CI 75–92.3%)
diagnostic outcome (n = 297) 8.6% (95%CI 5.2–13.3%) 35.4% (95%CI 28.9–42.3%) 89.5% (95%CI 84.5–93.3%)
LR+
CTA (n = 162) 1.07 (95%CI 1–1.2) 1.20 (95%CI 1–1.4) 2.37 (95%CI 1.3–4.4)
diagnostic outcome (n = 297) 1.04 (95%CI 1.0–1.1) 1.3 (95%CI 1.1–1.5) 3.35 (95%CI 2.1–5.4)
LR−
CTA (n = 162) 0.42 (95%CI 0.1–1.3) 0.54 (95%CI 0.3–1) 0.76 (95%CI 0.6–0.9)
diagnostic outcome (n = 297) 0.53 (95%CI 0.2–1.5) 0.45 (95%CI 0.3–0.8) 0.72 (95%CI 0.6–0.9)
Table 3. Diagnostic test characteristics of sST2 for diagnosis of acute aortic syndromes. ACutoff providing 
similar sensitivity to D-dimer (cutoff 500 ng/mL) in the CTA-based analysis; Bcutoff providing similar specificity 
to D-dimer (cutoff 500 ng/mL) in the CTA-based analysis; Ccutoff maximizing sensitivity and specificity 
(Youden’s method) in the CTA-based analysis. LR: likelihood ratio.
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Committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino) approved the study 
and written informed consent was obtained from participants or their authorized representatives. The study pro-
tocol conformed to the ethical guidelines (Declaration of Helsinki, 1975).
Selection of participants. From January 2017 to October 2018, outpatients aged ≥18 years were enrolled: 
(1) if they presented ≥1 red-flag symptom(s) of AAS (chest/abdominal/back pain, syncope, perfusion deficit) 
dating ≤14 days, and (2) if an AAS was considered in differential diagnosis by the attending physician. To allow 
immediate handling and storage of plasma samples in the laboratory, enrolment was limited to daytime, from 8 
a.m. to 8 p.m., 7 days/week.
Laboratory analyses. During the ED visit, patients underwent venipuncture for the routine blood tests 
deemed necessary by the attending physician. Blood samples were immediately sent to the local laboratory for 
automatic processing. D-dimer levels were measured urgently by the laboratory on trisodium citrate-plasma sam-
ples, using the STA-Liatest D-Di assay (Stago, Asnières sur Seine, France). This is a rapid, automated, quantitative 
immune-turbidimetric quantitative assay. The results of the D-dimer assay were available live to the attending 
physicians, for clinical decisions. For sST2 measurement, for each patient an EDTA-plasma sample aliquot was 
rapidly obtained in the laboratory and stored at −80 °C until further processing. The levels of sST2 were measured 
subsequently on thawed plasma batches and were not available to attending physicians for clinical use.
sST2 assay. The concentrations of plasma sST2 were measured using the Critical Diagnostics Presage® ST2, 
a quantitative sandwich type ELISA (enzyme-linked immunosorbent assay) which uses monoclonal antibodies. 
Human endogenous ST2 demonstrated stability in all the following conditions: storage at 20 °C for 48 h, at 4 °C 
for 7 days, at −20 °C and −80 °C for 18 months. The assay precision assessment was performed according to the 
CLSI (Clinical and Laboratory Standards Institute) EP5-A standards. Intra-series coefficient of variation (CVa) 
and total CVa were 6.5% and 9.1%, respectively, at an average concentration of 16.9 ng/mL, 3.4% and 5.5% at a 
mean concentration of 33.1 ng/mL, 3.8% and 6.3% at an average concentration of 68.7 ng/mL, 2.4% and 4.8% at an 
average concentration of 159.1 ng/mL. The limit of quantification is 2.4 ng/mL and the dynamic range of measure-
ment is from 2.4 ng/mL up to 200 ng/mL. There are no significant interferences with total proteins, triglycerides, 
hemoglobin, cholesterol, bilirubin.
In a subset of 86 patients (24 AAS, 62 AltD) with sufficient plasma aliquots, sST2 levels were assayed also 
with the human ST2/IL-1 R4s assay by R&D Systems (DY523B-05; Minneapolis, MN, USA), according to the 
manufacturer’s protocol. Passing and Bablok regression analyses were used for method comparison. The Cusum 
test showed non-significant deviation from linearity (p = 0.88). Non-parametric correlation analysis revealed a 
Spearman’s coefficient of rank correlation (ρs) of 0.29 (95%CI, 0.11–0.45; P = 0.003) between results obtained with 
the Presage and the R&D assay.
Case adjudication. All diagnostic and clinical decisions were performed at the discretion of the treating 
providers, independent of study participation. For each patient, a dichotomic case adjudication (AAS vs alterna-
tive diagnosis, AltD) was made by two independent reviewers expert in Emergency Medicine and acute aortic 
syndromes, blinded to sST2 and D-dimer levels, who evaluated all available clinical data (ED/hospital/surgical 
charts, imaging data, blood test results) obtained within 30 days after the index ED visit, including the results of 
a 30-day clinical or structured telephone follow-up contact performed by a research staff. In case of discordance, 
cases were adjudicated after discussion. Patients were instructed to return to the ED in case of new, worsening or 
recurrent symptoms.
AAS was defined by evidence of an AAS on CTA, TEE, magnetic resonance angiography, surgery or autopsy. If 
advanced imaging data, surgical or autopsy data was not available, an AAS was considered absent: (1) in patients 
admitted to hospital, if an alternative diagnosis was available, (2) in patients dismissed from the ED, if they had 
an uncomplicated clinical course or if an alternative diagnosis was made during the 30-day follow-up period.
Outcome measures and sample size. Primary outcomes were the diagnostic test characteristics of sST2 
for AASs. To calculate sample size, we hypothesized to test an AUC difference of 10% between sST2 and D-dimer, 
for diagnosis of AASs. Based on metanalysis of available studies, we assumed for D-dimer an AUC of 95%23. 
Using an alpha of 0.05 (one sided) and a power of 0.8, we needed to include about 250 patients to reject the null 
hypothesis.
Data analysis. Continuous variables were expressed as median and IQR (interquartile range, indicated as 
25th to 75th percentile values). Dichotomous data were expressed as proportions (in % value) with their 95% 
confident interval (CI), computed using Wilson’s method. The diagnostic performance of the biomarkers was 
evaluated with ROC analysis. AUCs were calculated and compared per Hanley & McNeil. For specified cutoffs, 
sensitivity, specificity and positive/negative likelihood ratios (LR+/LR−) were computed with their 95%CI. The 
tests used for statistical comparison were Pearson’s χ2 test (dichotomous data), Mann-Whitney U-test for inde-
pendent samples (continuous data, two-groups) and Kruskal-Wallis test for independent samples (continuous 
data, multiple groups). P-values were two-sided and P < 0.05 was considered significant. The analysis was per-
formed with SPSS statistical package (ver. 25.0, SPSS Inc., Chicago, Illinois) and MedCalc software (ver 18.11.3).
Data availability
The datasets generated during and analyzed during the current study are available from the corresponding author 
on reasonable request.
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